Literature DB >> 8951643

Distribution of pituitary adenylate cyclase activating polypeptide (PACAP) immunoreactivity in the hypothalamus and extended amygdala of the rat.

H D Piggins1, J A Stamp, J Burns, B Rusak, K Semba.   

Abstract

Pituitary adenylate cyclase activating polypeptide (PACAP) is found in two forms of 27 and 38 amino acids (PACAP-27 and PACAP-38 respectively) in the mammalian central nervous system. Using antibodies to these two forms of PACAP, we examined the distribution of PACAP immunoreactivity in the rat hypothalamus and a number of extrahypothalamic areas. The patterns of immunostaining for PACAP-27 and PACAP-38 were similar: prominent terminal labelling was present in the retrochiasmatic area, median eminence, and posterior periventricular nucleus of the hypothalamus as well as the bed nucleus of the stria terminalis and amygdaloid complex. After colchicine treatment, immunopositive cell bodies were found in the preoptic region of the periventricular zone of the hypothalamus, the suprachiasmatic and paraventricular hypothalamic nuclei, neural structures adjacent to the median eminence (including the retrochiasmatic area, arcuate nucleus, ventromedial hypothalamus, and tuber cinereum), and the lateral mammillary and supramammillary nuclei. In all these areas, immunolabelling appeared specific since it was abolished by preabsorption of primary antisera with the appropriate PACAP peptide. However, the number of immunopositive cells in the suprachiasmatic nucleus was also reduced by preabsorption of PACAP-27/38 antisera with vasoactive intestinal polypeptide, suggesting that a subpopulation of cells in the suprachiasmatic nucleus express a peptide which has significant sequence homology with both PACAP-27/38 and vasoactive intestinal polypeptide. The distribution of PACAP immunoreactivity throughout the hypothalamus, bed nucleus of the stria terminalis, and amygdala suggests the involvement of PACAP in a number of processes including limbic, autonomic, and neuroendocrine functions as well as regulation of the circadian pacemaker.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8951643     DOI: 10.1002/(SICI)1096-9861(19961209)376:2<278::AID-CNE9>3.0.CO;2-0

Source DB:  PubMed          Journal:  J Comp Neurol        ISSN: 0021-9967            Impact factor:   3.215


  39 in total

1.  Activation of NMDA receptors in the suprachiasmatic nucleus produces light-like phase shifts of the circadian clock in vivo.

Authors:  E M Mintz; C L Marvel; C F Gillespie; K M Price; H E Albers
Journal:  J Neurosci       Date:  1999-06-15       Impact factor: 6.167

2.  Neuropeptide-mediated calcium signaling in the suprachiasmatic nucleus network.

Authors:  Robert P Irwin; Charles N Allen
Journal:  Eur J Neurosci       Date:  2010-10-12       Impact factor: 3.386

3.  Pituitary Adenylate Cyclase-Activating Peptide in the Central Amygdala Causes Anorexia and Body Weight Loss via the Melanocortin and the TrkB Systems.

Authors:  Attilio Iemolo; Antonio Ferragud; Pietro Cottone; Valentina Sabino
Journal:  Neuropsychopharmacology       Date:  2015-02-04       Impact factor: 7.853

4.  CRF mediates the anxiogenic and anti-rewarding, but not the anorectic effects of PACAP.

Authors:  Riccardo Dore; Attilio Iemolo; Karen L Smith; Xiaofan Wang; Pietro Cottone; Valentina Sabino
Journal:  Neuropsychopharmacology       Date:  2013-05-09       Impact factor: 7.853

5.  Behavioral effects of local microinfusion of pituitary adenylate cyclase activating polypeptide (PACAP) into the paraventricular nucleus of the hypothalamus (PVN).

Authors:  Seth D Norrholm; Mahasweta Das; Gábor Légrádi
Journal:  Regul Pept       Date:  2005-05-15

6.  Pituitary adenylate cyclase-activating polypeptide induces postsynaptically expressed potentiation in the intra-amygdala circuit.

Authors:  Jun-Hyeong Cho; Ko Zushida; Gleb P Shumyatsky; William A Carlezon; Edward G Meloni; Vadim Y Bolshakov
Journal:  J Neurosci       Date:  2012-10-10       Impact factor: 6.167

7.  Altered psychomotor behaviors in mice lacking pituitary adenylate cyclase-activating polypeptide (PACAP).

Authors:  H Hashimoto; N Shintani; K Tanaka; W Mori; M Hirose; T Matsuda; M Sakaue; J Miyazaki; H Niwa; F Tashiro; K Yamamoto; K Koga; S Tomimoto; A Kunugi; S Suetake; A Baba
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-30       Impact factor: 11.205

8.  PACAP in the BNST produces anorexia and weight loss in male and female rats.

Authors:  Margaret Kocho-Schellenberg; Kimberly R Lezak; Olivia M Harris; Erin Roelke; Niklas Gick; Inyop Choi; Shaquille Edwards; Emily Wasserman; Donna J Toufexis; Karen M Braas; Victor May; Sayamwong E Hammack
Journal:  Neuropsychopharmacology       Date:  2014-01-17       Impact factor: 7.853

9.  PACAP increases Arc/Arg 3.1 expression within the extended amygdala after fear conditioning in rats.

Authors:  Edward G Meloni; Karen T Kaye; Archana Venkataraman; William A Carlezon
Journal:  Neurobiol Learn Mem       Date:  2018-11-17       Impact factor: 2.877

10.  High-resolution characterization of a PACAP-EGFP transgenic mouse model for mapping PACAP-expressing neurons.

Authors:  Michael C Condro; Anna Matynia; Nicholas N Foster; Yukio Ago; Abha K Rajbhandari; Christina Van; Bhavaani Jayaram; Sachin Parikh; Anna L Diep; Eileen Nguyen; Victor May; Hong-Wei Dong; James A Waschek
Journal:  J Comp Neurol       Date:  2016-06-03       Impact factor: 3.215

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.